Mesoblast
MESO
About: Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
Employees: 73
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
30% more call options, than puts
Call options by funds: $7.27M | Put options by funds: $5.59M
8% more funds holding
Funds holding: 66 [Q1] → 71 (+5) [Q2]
2.41% more ownership
Funds ownership: 0.3% [Q1] → 2.72% (+2.41%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 20
21% less capital invested
Capital invested by funds: $48M [Q1] → $37.9M (-$10M) [Q2]
Financial journalist opinion
Based on 3 articles about MESO published over the past 30 days
